Status:

COMPLETED

Validation of a Simplified MATRx Plus

Lead Sponsor:

Zephyr Sleep Technologies

Conditions:

Obstructive Sleep Apnea

Eligibility:

All Genders

21-80 years

Brief Summary

Sleep apnea (OSA) is a condition in which the air passage in the throat closes or partly closes during sleep and repeatedly interrupts breathing. The standard treatment for sleep apnea is continuous p...

Detailed Description

Sleep apnea (OSA) is a condition in which the air passage in the throat closes or partly closes during sleep and repeatedly interrupts breathing. The standard treatment for sleep apnea is continuous p...

Eligibility Criteria

Inclusion

  • Aged between 21 and 80 years
  • Obstructive sleep apnea (ODI \> 10 h-1)
  • Body mass index \< 45 kg/m2
  • Neck circumference \< 50 cm
  • Absence of severe oxyhemoglobin desaturation during sleep, indicated by a mean value of oxyhemoglobin saturation (SaO2) \> 87%
  • Mandibular range of motion \> 5 mm
  • Adequate dentition (10 upper and 10 lower teeth)
  • Ability to understand and provide informed consent
  • Ability and willingness to meet the required schedule

Exclusion

  • Inability to breathe comfortably through the nose
  • Central Sleep Apnea (\> 50% of apneas are central)
  • Anticipated change in medical therapy that could alter the severity of OSA during the protocol
  • Anticipated change in body weight (5% or more) during the protocol
  • Symptomatic, non-respiratory sleep disorder, e.g., restless leg syndrome or chronic insomnia
  • Severe respiratory disorder(s) other than sleep disordered breathing
  • Loose teeth, faulty restorations, or advanced periodontal disease
  • Participation in other studies that could interfere with study protocol
  • Pregnant or nursing
  • Heart failure
  • Cerebral vascular incident within the last 12 months
  • Use of pacemaker or other life supporting device
  • Regular use of CPAP or oral appliance therapy within 5 days of the PSG or HSAT (individuals on therapy wishing to participate may opt to cease therapy for the 5 nights prior to each test)

Key Trial Info

Start Date :

February 6 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 1 2021

Estimated Enrollment :

59 Patients enrolled

Trial Details

Trial ID

NCT03812692

Start Date

February 6 2019

End Date

March 1 2021

Last Update

March 4 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zephyr Sleep Technologies

Calgary, Alberta, Canada, T2H-2C3